Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Abemaciclib and Gemcitabine in Rb+ Sarcomas
NCT06498648Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib in soft tissue sarcoma (STS), leiomyosarcoma (LMS), dedifferentiated liposarcoma (DDL), sponsored by National Cancer Institute. Started Mar 2026; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
soft tissue sarcoma (STS)leiomyosarcoma (LMS)dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NCT06498648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06498648.